ethyl 4-(1-fluoroethyl)benzoate | 155671-16-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 4-(1-fluoroethyl)benzoate
• CAS: 155671-16-2
• 化学式: C₁₁H₁₃FO₂
• 分子量: 196.221
• InChiKey: KBXSBNQMIAUMCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-乙基苯甲酸乙酯 在 triethylamine tris(hydrogen fluoride) 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 4.2h， 以46%的产率得到ethyl 4-(1-fluoroethyl)benzoate
  参考文献：
  名称：

  Chemo‐ and Site‐Selective Electro‐Oxidative Alkane Fluorination by C(sp ³ )−H Cleavage

  摘要：

  AbstractElectrochemical fluorinations of C(sp3)−H bonds with a nucleophilic fluoride source have been accomplished in a chemo‐ and site‐selective fashion, avoiding the use of electrophilic F+ sources and stoichiometric oxidants. The introduced metal‐free strategy exhibits high functional group tolerance, setting the stage for late‐stage fluorinations of biorelevant motifs. The synthetic utility of the C(sp3)−H fluorination was reflected by subsequent one‐pot arylation of the generated benzylic fluorides.

  DOI：

  10.1002/chem.202201654

文献信息

• <i>cis</i>-Specific Hydrofluorination of Alkenylarenes under Palladium Catalysis through an Ionic Pathway
  作者：Enrico Emer、Lukas Pfeifer、John M. Brown、Véronique Gouverneur

  DOI：10.1002/anie.201310056

  日期：2014.4.14

  paper describes the hydrofluorination of alkenes through sequential H− and F+ addition under palladium catalysis. The reaction is cis specific, thus providing access to benzylic fluorides. The mechanism of this reaction involves an ionic pathway and is distinct from known hydrofluorinations involving radical intermediates. The first catalytic enantioselective hydrofluorination is also disclosed.

  本文描述了通过连续的^ h烯烃的氢氟化-和F +除了在钯催化下。该反应是顺式 特异性的，因此提供了获得苄基氟化物的途径。该反应的机理涉及离子途径，并且与涉及自由基中间体的已知氢氟化反应不同。还公开了第一催化对映选择性氢氟化。
• [EN] HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS<br/>[FR] UTILISATION DE DÉRIVÉS HÉTÉROARYLCARBOXAMIDES COMME INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2017072020A1

  公开（公告）日：2017-05-04

  The present invention relates to compounds of general formula I, wherein D1 to D3, A, R1, R2, Y and n are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.

  本发明涉及通式I的化合物，其中D1至D3、A、R1、R2、Y和n的定义如权利要求书中所述，该化合物具有有价值的药理特性，特别是作为血浆激肽酶的抑制剂。这些化合物适用于治疗和预防可以受到血浆激肽酶抑制影响的疾病，例如糖尿病并发症，尤其适用于治疗与糖尿病视网膜病变和糖尿病黄斑水肿相关的视网膜血管通透性。